Source news

globenewswire News

20 stories
globenewswire

Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress

June 29, 2026Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAPandUpdate on Serenta ProgressBiodexa Pharmaceuticals PLC NASDAQ:BDRX (“Biodexa” or “the Company”), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prev…

GlobeNewswire en
ETFsStocksUS
globenewswire

Cycurion, Inc. Enters into Asset Purchase Agreement to Acquire Kustom Entertainment’s Legacy Video Solutions Segment, Delivering Non-Dilutive Scale, Access to Approximately 1,000 New Clients and a Robust Portfolio of Approximately 58 Patents

MCLEAN, Va., June 29, 2026 (GLOBE NEWSWIRE) -- Cycurion, Inc. NASDAQ:CYCU (“Cycurion” or the “Company”), a leading provider of AI-driven cybersecurity, IT security solutions, and managed services, today announced that it has entered into an Asset Purchase Agreement, dated June 24, 2026 (the “Asset…

GlobeNewswire en
StocksUS
globenewswire

Mingteng International Reaches New Milestone in Global Expansion with Overseas Orders Serving Markets in Serbia, Vietnam and Mexico

Wuxi, China, June 29, 2026 (GLOBE NEWSWIRE) -- Mingteng International Corporation Inc. (the “Company” or “Mingteng International”) NASDAQ:MTEN, an automotive mold developer and supplier in China, today announced that, its wholly-owned subsidiary, Wuxi Mingteng Mould Technology Co., Ltd. (“Wuxi Ming…

GlobeNewswire en
StocksCN
globenewswire

New PROSPER Data Demonstrate Real-World Impact of Mogamulizumab on Symptoms and Health-Related Quality of Life in Mycosis Fungoides and Sézary Syndrome

PRINCETON, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd TSE:4151, today announced positive results from PROSPER, a real-world observational study of mogamulizumab in adults with mycosis fungoides (MF) or Sézary syndrome (SS). In the stu…

GlobeNewswire en
StocksJP
globenewswire

Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis

ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and EuropeFirst patient enrollment anticipated in the second half of 2026; primary efficacy results expected in the second half of 2027IND clearance marks a major development…

GlobeNewswire en
ETFsStocksUS
globenewswire

Star Equity Holdings Added to the Russell Microcap® Index

OLD GREENWICH, Conn., June 29, 2026 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. NASDAQ:STRR and STRRP) ("Star" or the "Company"), a diversified holding company, announced today the Company’s common stock has been added to the Russell Microcap® Index following the 2026 Russell indexes reconstitut…

GlobeNewswire en
indexStocksUS
globenewswire

Stran Expands Strategic Casino Market Presence with Industry Veteran Kevin Lewis to Accelerate Growth and Client Impact

Seasoned Promotional Products Leader Kevin Lewis Joins Stran to Drive $5M+ Book and Extend Account Reach in Las Vegas and Gaming SectorQuincy, MA, June 29, 2026 (GLOBE NEWSWIRE) -- Stran & Company, Inc. ("Stran" or the "Company") NASDAQ:SWAG NASDAQ:SWAGW, a leading outsourced marketing solutions pr…

GlobeNewswire en
StocksUS
globenewswire

WeShop Added to Russell 3000® and Russell Microcap® Indexes

NEW YORK, June 29, 2026 (GLOBE NEWSWIRE) -- WeShop Holdings Limited (“WeShop” or the “Company”) NASDAQ:WSHP, the first community-owned social commerce platform, has been added to the broad U.S. market Russell 3000® Index as part of FTSE Russell’s annual reconstitution of its stock indexes, effectiv…

GlobeNewswire en
index
globenewswire

HOFSETH BIOCARE ASA: MANDATORY NOTIFICATION OF TRADE

Reference is made to the stock exchange announcements from Hofseth BioCare ASA ("HBC" or the "Company") published on 26 June 2026 and 29 June 2026 regarding a private placement (the "Private Placement") of new ordinary shares ("Offer Shares") at a fixed price per share of NOK 1.30 (the "Offer Price…

GlobeNewswire en
StocksNO
globenewswire

FERRARI N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM

Maranello (Italy), June 29, 2026 – Ferrari N.V. (NYSE/EXM:RACE (“Ferrari” or the “Company”) informs that the Company has purchased, under the Euro 250 million share buyback program announced on April 10, 2026, as the second tranche of the multi-year share buyback program of approximately Euro 3.5 b…

GlobeNewswire en
StocksIT